Sea Buckthorn for Health & Longevity

Created on 11/12/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Unknown – Audit

Sea buckthorn is a plant used as oral oils and extracts for blood fats, dry eyes, vaginal comfort, and digestion. Trials support targeted uses over broad longevity rejuvenation: modest blood fat gains only when starting levels are abnormal, and single-team evidence for seasonal dry eye, vaginal lining health after menopause, fatty liver markers, and constipation. Multi-month safety is generally favorable; varied plant preparations and commercial ties temper confidence. (Full Review)

Protocol

Standardized supercritical oil regimen
2,000–5,000 mg/day oral oil
Trial doses of 2 g/day for dry eye and 3 g/day for vaginal lining health after menopause
Competing extract and food regimens
500–2,000 mg/day dry extract
500 mg/day fruit or polyphenol extract; whole-food trials use 28 g/day berries or 90 mL/day puree
Time of day
Morning and evening meals
Oil softgels or dry extracts paired with fat-containing meals per common practice, for potential flavonol absorption and reduced digestive upset
Time to effect
Chronic Constipation & Bowel Function Relief
28 days
Bowel regularity and stool form improved in a single trial of 500 mg/day dry fruit extract
Vaginal Epithelial Integrity in Postmenopausal Atrophy
3 months
Vaginal lining integrity improved in a single trial of 3 g/day oral oil
Dry Eye Symptom & Tear Osmolarity Relief
3 months
Cold-season tear salt concentration rise and eye redness blunted in a single trial of 2 g/day oral oil

Benefits

Contraindications
  • Pregnancy and lactation
  • End-stage kidney disease on maintenance hemodialysis
  • Patients within 14 days of elective surgery or with active bleeding disorders
  • Individuals with known hypersensitivity to Hippophae rhamnoides or Elaeagnaceae species
  • Decompensated cirrhosis (Child-Pugh Class C)
Key Interactions
Theoretical (inferred from mechanism)
  • Prescription anticoagulants (warfarin) and antiplatelets (clopidogrel)
  • Over-the-counter NSAIDs (aspirin)
  • Prescription antihypertensives (amlodipine) and antidiabetics (metformin)
  • Antithrombotic and glucose-lowering supplements (fish oil, berberine)
  • CYP2C9 (losartan) and CYP2D6 (metoprolol) substrates and elective surgery

Risk & Side Effects

  • High:
  • Medium: Serum phosphate, sodium & iron shifts in hemodialysis
  • Low: Gastrointestinal intolerance; mucosal bleeding & impaired clotting; carotenoderma
  • Speculative: Saturated palmitic acid cardiometabolic burden; additive low blood pressure or low blood sugar

Monitoring

Marker Target Why
Fasting Lipid Panel (Triglycerides, LDL-C, HDL-C) No established target; triglyceride and LDL-C reduction and HDL-C rise from individual baseline Efficacy check when baseline blood lipids are abnormal (12-hour fast)
Plasma Phosphate, Sodium & Iron Phosphate 2.5–4.5 mg/dL; Sodium 135–145 mmol/L; Iron 60–170 µg/dL (standard reference range) Safety check for mineral shifts in impaired kidney function
Tear Film Osmolarity No established target; smaller cold-season rise from individual baseline Efficacy check for cold-season tear concentration rise in dry eye

Cadence: Baseline testing before starting; ongoing monitoring rechecks bowel logs at 4 weeks, blood electrolytes and iron at 4–8 weeks in impaired kidney function, and fasting lipids, tear salt concentration, and ocular or vaginal symptoms at 8–12 weeks (then every 6–12 months during continued use).

Qualitative Assessment

  • Ocular and vaginal comfort: Fewer red, burning eye days and better vaginal comfort by week 12.
  • Bowel regularity: Higher weekly complete bowel movements and normalized stool form by week 4.
  • Skin and bleeding check: No yellow-orange skin tinting or unexplained bruising.